NCT04826159CompletedPhase 2
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
A Pharmacodynamic Study to Evaluate the Effects of IMB-1018972 on Myocardial Energetics, Metabolism, and Function in Patients With Type 2 Diabetes.
Source: ClinicalTrials.gov · Last updated 29 Jun 2025
Brief summary (registry, in English)
The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- First submitted
- 18 Mar 2021
- Start date
- 21 Apr 2021
- Primary completion date
- 6 Aug 2024
- Lead sponsor
- Imbria Pharmaceuticals, Inc.
- Diseases
- Heart failure, Obesity, Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT04826159
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 49
- From 21 Apr 2021 to the primary completion date, 6 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Clinically significant concurrent condition which could prevent the patient from performing any of the protocol-specified assessments, represent a safety concern if the patient participates in the trial or could confound trial assessments of safety or tolerability
Other illness
- Uncontrolled hypertension
- More than mild to moderate valvular heart disease
- History of sustained ventricular tachycardia or cardiac arrest
Other
- Contraindication to magnetic resonance scanning
- Atrial fibrillation
- Inability to exercise (Stage 2 only)
Who the study is looking for
- Diagnosis of type 2 diabetes
- Elevated HbA1c
- Elevated BMI
- Preserved left ventricular ejection fraction
- Diagnosis of HFpEF (Stage 2 only)
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oxford University Hospital Coordinator of this site? Confirm its status | Oxford | United Kingdom | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.